On­ly five months af­ter a Se­ries A launch, Taysha goes pub­lic with $157M IPO

As has been the trend in 2020, Taysha Gene Ther­a­pies has be­come the lat­est biotech to make a quick as­cent from a small, pri­vate­ly-fund­ed com­pa­ny to en­joy­ing its very own Nas­daq tick­er.

The Dal­las-based biotech raised $157 mil­lion for its IPO af­ter pric­ing shares at $20 apiece Thurs­day, the high-point of its ex­pect­ed range. Ini­tial­ly peg­ging $100 mil­lion in fi­nanc­ing, Taysha of­fered a lit­tle less than 8 mil­lion shares and will trade un­der the $TSHA sym­bol.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.